| 利用者成果(英) |
|
21561
Suzuki H, Nagase S, Saito C, Takatsuka A, Nagata M, Honda K, Kaneda Y, Nishiya Y, Honda T, Ishizaka T, Nakamura K, Nakada T, Abe Y, Agatsuma T.
Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, is Efficacious in Human Ovarian and Kidney Cancer Models.
Mol Cancer Ther
2024
PubMed ID: 38205802
DOI: 10.1158/1535-7163.MCT-23-0287
|
|
21271
Ferrari AJ, Rawat P, Rendulich HS, Annapragada AV, Kinose Y, Zhang X, Devins K, Budina A, Scharpf RB, Mitchell MA, Tanyi JL, Morgan MA, Schwartz LE, Soong TR, Velculescu VE, Drapkin R.
H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.
JCI Insight
2023
8(12)
PubMed ID: 37345659
DOI: 10.1172/jci.insight.164995
|
|
21399
Akashi H, Yachida N, Ueda H, Yamaguchi M, Yamawaki K, Tamura R, Suda K, Ishiguro T, Adachi S, Nagase Y, Ueda Y, Ueda M, Abiko K, Kagabu M, Baba T, Nakaoka H, Enomoto T, Murai J, Yoshihara K.
SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma.
Mol Cancer Ther
2023
PubMed ID: 37717249
DOI: 10.1158/1535-7163.MCT-23-0257
|
|
21429
Thorel L, Morice PM, Paysant H, Florent R, Babin G, Thomine C, Perréard M, Abeilard E, Giffard F, Brotin E, Denoyelle C, Villenet C, Sebda S, Briand M, Joly F, Dolivet E, Goux D, Blanc-Fournier C, Jeanne C, Villedieu M, Meryet-Figuiere M, Figeac M, Poulain L, Weiswald LB.
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
J Exp Clin Cancer Res
2023
42(1):260
PubMed ID: 37803448
DOI: 10.1186/s13046-023-02809-8
|
|
21483
Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y.
Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.
Sci Rep
2023
13(1):20292
PubMed ID: 37985723
DOI: 10.1038/s41598-023-47637-0
|
|
20728
Mehner C, Hockla A, Coban M, Madden B, Estrada R, Radisky DC, Radisky ES.
Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.
J Biol Chem
2022
102146
PubMed ID: 35716777
DOI: 10.1016/j.jbc.2022.102146
|
|
20211
Oyama Y, Shigeta S, Tokunaga H, Tsuji K, Ishibashi M, Shibuya Y, Shimada M, Yasuda J, Yaegashi N.
CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
PLoS One
2021
16(6):e0251079
PubMed ID: 34161330
DOI: 10.1371/journal.pone.0251079
|
|
14932
Ota Y, Koizume S, Nakamura Y, Yoshihara M, Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, Miyagi E, Miyagi Y.
Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix
Oncol Rep
2021
45(3):1023-1032
PubMed ID: 33650653
DOI: 10.3892/or.2021.7944
|
|
17036
Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, Huntsman DG, Kossenkov AV, Speicher DW, Schug ZT, Van Dang C, Zhang R.
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma
Nat Cancer
2021
2(2):189-200
PubMed ID: 34085048
DOI: 10.1038/s43018-020-00160-x
|
|
9662
Ji JX, Cochrane DR, Tessier-Cloutier B, Chen SY, Ho G, Pathak KV, Alcazar IN, Farnell D, Leung S, Cheng A, Chow C, Colborne S, Negri GL, Kommoss F, Karnezis A, Morin GB, McAlpine JN, Gilks CB, Weissman BE, Trent JM, Hoang L, Pirrotte P, Wang Y, Huntsman DG.
Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Clin Cancer Res
2020
26(16):4402-4413
PubMed ID: 32409304
DOI: 10.1158/1078-0432.CCR-19-1905
|
|
13109
De Haven Brandon A, Box G, Hallsworth A, Court W, Matthews N, Herodek B, Arteagabeitia AB, Valenti M, Kirkin V.
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.
Sci Rep
2020
PubMed ID: 32612269
DOI: 10.1038/s41598-020-67533-1
|
|
13249
Minagawa Y, Ishino K, Wada R, Kudo M, Naito Z, Takeshita T, Ohashi R.
High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma.
Anticancer Res
2020
PubMed ID: 32988887
DOI: 10.21873/anticanres.14576
|
|
14802
Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL.
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers
Cancer Res
2020
80(20):4514-4526
PubMed ID: 32859605
DOI: 10.1158/0008-5472.CAN-19-3971
|
|
14853
Arildsen NS, Hedenfalk I.
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
Oncotarget
2020
11(40):3660-3674
PubMed ID: 33088426
DOI: 10.18632/oncotarget.27747
|
|
11322
Kato N, Sato Y, Kamataki A, Fukase M, Uchigasaki S, Kurose A.
PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
Hum. Pathol.
2019
PubMed ID: 30496799
DOI: 10.1016/j.humpath.2018.11.013
|
|
11632
Caumanns JJ, van Wijngaarden A, Kol A, Meersma GJ, Jalving M, Bernards R, van der Zee AGJ, Wisman GBA, de Jong S.
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Cancer Lett.
2019
PubMed ID: 31319139
DOI: 10.1016/j.canlet.2019.07.004
|
|
11966
Sahin ID, Jönsson JM, Hedenfalk I.
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
Oncotarget
2019
PubMed ID: 31857852
DOI: 10.18632/oncotarget.27363
|
|
12482
Kim HJ, Lee S, Oh YS, Chang HK, Kim YS, Hong SH, Kim JY, Park YW, Lee SJ, Song SW, Kim JJ, Heo K.
Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
Front Oncol
2019
9:571
PubMed ID: 31355133
DOI: 10.3389/fonc.2019.00571
|
|
14809
Yasuto Kinose, Dorothy Hallberg, Kai Doberstein, Gordon Mills, Tan Ince, Victor Velculescu, Fiona Simpkins, Ronny Drapkin
Abstract 1065: Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines forin vivodrug development
Tumor Biology
2019
DOI: 10.1158/1538-7445.am2019-1065
|
|
11075
Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Oncogene
2018
37(33):4611-4625
PubMed ID: 29760405
DOI: 10.1038/s41388-018-0300-6
|
|
11109
Le Naour A, Mevel R, Thibault B, Courtais E, Chantalat E, Delord JP, Couderc B, Guillermet-Guibert J, Martinez A.
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Oncotarget
2018
9(43):27220-27232
PubMed ID: 29930760
DOI: 10.18632/oncotarget.25513
|
|
10087
Sato M, Kawana K, Adachi K, Fujimoto A, Taguchi A, Fujikawa T, Yoshida M, Nakamura H, Nishida H, Inoue T, Ogishima J, Eguchi S, Yamashita A, Tomio K, Arimoto T, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.
Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
Oncol. Rep.
2017
37:1883-1888
PubMed ID: 28112360
DOI: 10.3892/or.2017.5398
|
|
10161
Sato M, Kawana K, Adachi K, Fujimoto A, Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Ogishima J, Eguchi S, Yamashita A, Tomio K, Wada-Hiraike O, Oda K, Nagamatsu T, Osuga Y, Fujii T.
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Int. J. Oncol.
2017
50:1431-1438
PubMed ID: 28259988
DOI: 10.3892/ijo.2017.3891
|
|
9659
Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich
Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Mol Cancer Ther
2017
16(5):850-860
PubMed ID: 28292935
DOI: 10.1158/1535-7163.MCT-16-0678
|
|
7404
Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A.
Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Mol. Carcinog.
2016
55:832-41
PubMed ID: 25856562
DOI: 10.1002/mc.22325
|
|
9636
Nozomu Yanaihara, Yukiko Noguchi 1, Misato Saito 1, Masataka Takenaka 1, Satoshi Takakura 2, Kyosuke Yamada 1, Aikou Okamoto 1
MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma
PLoS One
2016
11(9):e0162584
PubMed ID: 27612152
DOI: 10.1371/journal.pone.0162584
|
|
12611
Kato N, Kurotaki H, Uchigasaki S, Fukase M, Kurose A.
Ovarian clear cell carcinoma with plasma cell-rich inflammatory stroma: a clear cell carcinoma subgroup with distinct clinicopathological features
Histopathology
2016
68(4):588-95
PubMed ID: 26211695
DOI: 10.1111/his.12783
|
|
7410
Takenaka M, Saito M, Iwakawa R, Yanaihara N, Saito M, Kato M, Ichikawa H, Shibata T, Yokota J, Okamoto A, Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol.
2015
46:2389-98
PubMed ID: 25846456
DOI: 10.3892/ijo.2015.2951
|
|
14315
Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Mol Cancer Ther
2015
14(6):1495-503
PubMed ID: 25852062
DOI: 10.1158/1535-7163.MCT-15-0039
|
|
14956
Takata A, Terauchi M, Hiramitsu S, Uno M, Wakana K, Kubota T.
Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells
Int J Gynecol Cancer
2015
25(3):372-9
PubMed ID: 25514350
DOI: 10.1097/IGC.0000000000000340
|
|
15031
Takaya A, Peng WX, Ishino K, Kudo M, Yamamoto T, Wada R, Takeshita T, Naito Z.
Cystatin B as a potential diagnostic biomarker in ovarian clear cell carcinoma
Int J Oncol
2015
46(4):1573-81
PubMed ID: 25633807
DOI: 10.3892/ijo.2015.2858
|
|
15235
Amano Y, Mandai M, Yamaguchi K, Matsumura N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y, Konishi I.
Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival
Oncotarget
2015
6(28):26002-17
PubMed ID: 26318292
DOI: 10.18632/oncotarget.4692
|
|
9634
Kanako Shinjo, Yoriko Yamashita, Eiko Yamamoto, Shinya Akatsuka, Nozomi Uno, Akihiro Kamiya, Kaoru Niimi, Yuka Sakaguchi, Tetsuro Nagasaka, Takashi Takahashi, Kiyosumi Shibata, Hiroaki Kajiyama, Fumitaka Kikkawa, Shinya Toyokuni
Expression of Chromobox Homolog 7 (CBX7) Is Associated With Poor Prognosis in Ovarian Clear Cell Adenocarcinoma via TRAIL-induced Apoptotic Pathway Regulation
Int J Cancer
2014
135(2):308-18
PubMed ID: 24375438
DOI: 10.1002/ijc.28692
|
|
13692
Uno M, Saitoh Y, Mochida K, Tsuruyama E, Kiyono T, Imoto I, Inazawa J, Yuasa Y, Kubota T, Yamaoka S.
NF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression
PLoS One
2014
9(2):e88347.
PubMed ID: 24533079
DOI: 10.1371/journal.pone.0088347
|
|
14316
Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
BMC Cancer
2014
14:120
PubMed ID: 24559118
DOI: 10.1186/1471-2407-14-120
|
|
17115
Hirata Y, Murai N, Yanaihara N, Saito M, Saito M, Urashima M, Murakami Y, Matsufuji S, Okamoto A.
MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma
BMC Cancer
2014
14:799
PubMed ID: 25366985
DOI: 10.1186/1471-2407-14-799
|
|
9635
Yoriko Yamashita, Shinya Akatsuka, Kanako Shinjo, Yasushi Yatabe, Hiroharu Kobayashi, Hiroshi Seko, Hiroaki Kajiyama, Fumitaka Kikkawa, Takashi Takahashi, Shinya Toyokuni
Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates With Worsened Prognosis
PLoS One
2013
8(3):e57724
PubMed ID: 23469222
DOI: 10.1371/journal.pone.0057724
|
|
9669
Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa
Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells
Int J Oncol
2013
43(1):63-71
PubMed ID: 23670532
DOI: 10.3892/ijo.2013.1935
|
|
9657
Nozomu Yanaihara, Michael S Anglesio, Kazunori Ochiai, Yukihiro Hirata, Misato Saito, Chie Nagata, Yasushi Iida, Satoshi Takakura, Kyosuke Yamada, Tadao Tanaka, Aikou Okamoto
Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma
Int J Oncol
2012
41(3):1094-100
PubMed ID: 22751940
DOI: 10.3892/ijo.2012.1533
|
|
8331
Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.
Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition.
Int. J. Cancer
2011
128:94-104
PubMed ID: 20309881
DOI: 10.1002/ijc.25332
|
|
6298
Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.
Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
Int J Oncol
2008
32(6):1227-35
PubMed ID: 18497984
DOI: 10.3892/ijo_32_6_1227
|
|
15560
Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.
Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
Cancer Sci
2008
99:2365-72
PubMed ID: 19032364
DOI: 10.1111/j.1349-7006.2008.00988.x
|
|
2934
Akahira, Jun-ichi, Sugihashi, Youko, Suzuki, Takashi, Ito, Kiyoshi, Niikura, Hitoshi, Moriya, Takuya, Nitta, Makoto, Okamura, Hitoshi, Inoue, Satoshi, Sasano, Hironobu, Okamura, Kunihiro, Yaegashi, Nobuo
Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation.
Clin Cancer Res
2004
10:2687-93
PubMed ID: 15102672
DOI: 10.1158/1078-0432.ccr-03-0510
|
|
3796
Fukami T, Fukuhara H, Kuramochi M, Maruyama T, Isogai K, Sakamoto M, Takamoto S, Murakami Y.
Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines.
Int J Cancer
2003
107(1):53-9
PubMed ID: 12925956
DOI: 10.1002/ijc.11348
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
